2026-10-14T17:47:05Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34009593 2026-09-28T05:44:58Z category_696 portal_316 item_type_3 month_year_09_2026

Table 1_Clinical trial landscape and translational priorities for adoptive T-cell and NK-cell therapies in gynecologic malignancies.docx Qingyu Chen (3142713) Yuxin Zhu (3512447) Shilin Ye (25120140) Yaoyi Wang (4027283) Huilong Lin (11907077) Genetic Immunology adoptive cellular therapy CAR-T clinical trials gynecologic malignancies natural killer cells registry-based landscape TCR-T tumor-infiltrating lymphocytes Background<p>Adoptive T-cell and natural killer (NK)-cell therapies are expanding across solid tumors, but their registered development in gynecologic malignancies remains difficult to interpret because many studies use basket designs and registry records vary in detail.</p>Methods<p>We conducted a cross-sectional analysis of therapeutic adoptive T-cell and NK-cell trial records identified from TrialTrove, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform. Trials were classified into three mutually exclusive evidence-specificity groups: single gynecologic disease family specific, multiple gynecologic disease families only, and broader baskets including non-gynecologic cancers. We evaluated source sensitivity, target applicability, field-specific registry visibility, and the availability of posted registry safety results. A complementary registry-informed exploratory survey of 25 experts assessed translational barriers and development priorities using domain-specific 1–5 scales.</p>Results<p>Among 442 unique records screened, 211 therapeutic trials met the eligibility criteria. Of these, 43 were restricted to a single gynecologic disease family, 2 included multiple gynecologic disease families only, and 166 were broader basket trials permitting enrollment of non-gynecologic malignancies. The public-registry-linked and public-search-captured sensitivity subsets included 200 and 141 records, respectively, with broadly similar structural patterns across datasets. The landscape was predominantly early phase, with 149 Phase I and 50 Phase I/II trials. CAR-T, TIL, and TCR-T were the leading modalities, accounting for 79, 60, and 42 trials, respectively. Only 20 records had posted registry results with an adverse-event module, indicating limited availability of registry-reported safety data. In the exploratory expert survey, an immunosuppressive tumor microenvironment and a lack of gynecologic-specific cohorts were identified as leading barriers, whereas ovarian cancer, TIL therapy, MSLN, target reporting, and registry completeness emerged as prominent development priorities.</p>Conclusions<p>Registered cellular-therapy activity in gynecologic malignancies is broad but remains early phase, largely basket-derived, and unevenly visible in registry fields. Separating disease-specific trials from broader eligibility-only baskets, testing source sensitivity, and distinguishing modality biology from missing target reporting provide a more reproducible basis for future trial planning.</p> 2026-09-28T05:44:58Z Dataset Dataset 10.3389/fimmu.2026.1936815.s003 https://figshare.com/articles/dataset/Table_1_Clinical_trial_landscape_and_translational_priorities_for_adoptive_T-cell_and_NK-cell_therapies_in_gynecologic_malignancies_docx/34009593 CC BY 4.0